
Sign up to save your podcasts
Or


On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk’s Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:
Sponsors:
Koyfin: https://bit.ly/acquiredkoyfin
By Ben Gilbert and David Rosenthal4.6
276276 ratings
On our Novo Nordisk episode, we covered the business of Ozempic, the GLP-1 taking the world by storm. On this episode, we dive into the science of the molecule semaglutide (and its predecessor liraglutide) with the world expert on the topic, Lotte Bjerre Knudsen. Lotte is Novo Nordisk’s Chief Scientific Advisor, and led the research group back in the early 1990s that first invented the molecule. A few topics from our conversation:
Sponsors:
Koyfin: https://bit.ly/acquiredkoyfin

1,282 Listeners

534 Listeners

1,091 Listeners

2,364 Listeners

2,167 Listeners

227 Listeners

10,018 Listeners

516 Listeners

453 Listeners

350 Listeners

130 Listeners

472 Listeners

36 Listeners

43 Listeners

131 Listeners